1128 related articles for article (PubMed ID: 11046050)
1. Archaeosomes induce long-term CD8+ cytotoxic T cell response to entrapped soluble protein by the exogenous cytosolic pathway, in the absence of CD4+ T cell help.
Krishnan L; Sad S; Patel GB; Sprott GD
J Immunol; 2000 Nov; 165(9):5177-85. PubMed ID: 11046050
[TBL] [Abstract][Full Text] [Related]
2. Phosphatidylserine receptor-mediated recognition of archaeosome adjuvant promotes endocytosis and MHC class I cross-presentation of the entrapped antigen by phagosome-to-cytosol transport and classical processing.
Gurnani K; Kennedy J; Sad S; Sprott GD; Krishnan L
J Immunol; 2004 Jul; 173(1):566-78. PubMed ID: 15210818
[TBL] [Abstract][Full Text] [Related]
3. The potent adjuvant activity of archaeosomes correlates to the recruitment and activation of macrophages and dendritic cells in vivo.
Krishnan L; Sad S; Patel GB; Sprott GD
J Immunol; 2001 Feb; 166(3):1885-93. PubMed ID: 11160236
[TBL] [Abstract][Full Text] [Related]
4. Archaeosomes induce enhanced cytotoxic T lymphocyte responses to entrapped soluble protein in the absence of interleukin 12 and protect against tumor challenge.
Krishnan L; Sad S; Patel GB; Sprott GD
Cancer Res; 2003 May; 63(10):2526-34. PubMed ID: 12750276
[TBL] [Abstract][Full Text] [Related]
5. Archaeosomes as self-adjuvanting delivery systems for cancer vaccines.
Krishnan L; Dennis Sprott G;
J Drug Target; 2003; 11(8-10):515-24. PubMed ID: 15203920
[TBL] [Abstract][Full Text] [Related]
6. Generation of antigen specific CD8+ cytotoxic T cells following immunization with soluble protein formulated with novel glycoside adjuvants.
Sheikh NA; Rajananthanan P; Attard GS; Morrow WJ
Vaccine; 1999 Aug; 17(23-24):2974-82. PubMed ID: 10462232
[TBL] [Abstract][Full Text] [Related]
7. In vivo cross-presentation of a soluble protein antigen: kinetics, distribution, and generation of effector CTL recognizing dominant and subdominant epitopes.
Nelson D; Bundell C; Robinson B
J Immunol; 2000 Dec; 165(11):6123-32. PubMed ID: 11086045
[TBL] [Abstract][Full Text] [Related]
8. Induction of MHC class I presentation of exogenous antigen by dendritic cells is controlled by CD4+ T cells engaging class II molecules in cholesterol-rich domains.
Machy P; Serre K; Baillet M; Leserman L
J Immunol; 2002 Feb; 168(3):1172-80. PubMed ID: 11801652
[TBL] [Abstract][Full Text] [Related]
9. Whole protein and defined CD8(+) and CD4(+) peptides linked to penetratin targets both MHC class I and II antigen presentation pathways.
Pouniotis DS; Esparon S; Apostolopoulos V; Pietersz GA
Immunol Cell Biol; 2011 Nov; 89(8):904-13. PubMed ID: 21383765
[TBL] [Abstract][Full Text] [Related]
10. CpG-DNA activates in vivo T cell epitope presenting dendritic cells to trigger protective antiviral cytotoxic T cell responses.
Vabulas RM; Pircher H; Lipford GB; Häcker H; Wagner H
J Immunol; 2000 Mar; 164(5):2372-8. PubMed ID: 10679072
[TBL] [Abstract][Full Text] [Related]
11. Archaeosome vaccine adjuvants induce strong humoral, cell-mediated, and memory responses: comparison to conventional liposomes and alum.
Krishnan L; Dicaire CJ; Patel GB; Sprott GD
Infect Immun; 2000 Jan; 68(1):54-63. PubMed ID: 10603368
[TBL] [Abstract][Full Text] [Related]
12. Analysis of the role of MHC class II presentation in the stimulation of cytotoxic T lymphocytes by antigens targeted into the exogenous antigen-MHC class I presentation pathway.
Rock KL; Clark K
J Immunol; 1996 May; 156(10):3721-6. PubMed ID: 8621907
[TBL] [Abstract][Full Text] [Related]
13. Bacterial heat shock proteins promote CD91-dependent class I MHC cross-presentation of chaperoned peptide to CD8+ T cells by cytosolic mechanisms in dendritic cells versus vacuolar mechanisms in macrophages.
Tobian AA; Canaday DH; Boom WH; Harding CV
J Immunol; 2004 May; 172(9):5277-86. PubMed ID: 15100266
[TBL] [Abstract][Full Text] [Related]
14. Class I- and class II-reactive TCRs coexpressed on CD4+ T cells both trigger CD4/CD8-shared and CD4-unique functions.
Asnagli H; Schmitt-Verhulst AM; Guimezanes A
J Immunol; 1997 May; 158(10):4533-42. PubMed ID: 9144464
[TBL] [Abstract][Full Text] [Related]
15. In vivo augmentation of tumor-specific CTL responses by class I/peptide antigen complexes on microspheres (large multivalent immunogen).
Goldberg J; Shrikant P; Mescher MF
J Immunol; 2003 Jan; 170(1):228-35. PubMed ID: 12496404
[TBL] [Abstract][Full Text] [Related]
16. Cross-priming of T cell responses by synthetic microspheres carrying a CD8+ T cell epitope requires an adjuvant signal.
Boisgérault F; Rueda P; Sun CM; Hervas-Stubbs S; Rojas M; Leclerc C
J Immunol; 2005 Mar; 174(6):3432-9. PubMed ID: 15749877
[TBL] [Abstract][Full Text] [Related]
17. Rapid clonal expansion and prolonged maintenance of memory CD8+ T cells of the effector (CD44highCD62Llow) and central (CD44highCD62Lhigh) phenotype by an archaeosome adjuvant independent of TLR2.
Krishnan L; Gurnani K; Dicaire CJ; van Faassen H; Zafer A; Kirschning CJ; Sad S; Sprott GD
J Immunol; 2007 Feb; 178(4):2396-406. PubMed ID: 17277146
[TBL] [Abstract][Full Text] [Related]
18. Ovalbumin injected with complete Freund's adjuvant stimulates cytolytic responses.
Ke Y; Li Y; Kapp JA
Eur J Immunol; 1995 Feb; 25(2):549-53. PubMed ID: 7875219
[TBL] [Abstract][Full Text] [Related]
19. Bone marrow-generated dendritic cells pulsed with a class I-restricted peptide are potent inducers of cytotoxic T lymphocytes.
Porgador A; Gilboa E
J Exp Med; 1995 Jul; 182(1):255-60. PubMed ID: 7540653
[TBL] [Abstract][Full Text] [Related]
20. Retrovirally transduced bone marrow-derived dendritic cells require CD4+ T cell help to elicit protective and therapeutic antitumor immunity.
De Veerman M; Heirman C; Van Meirvenne S; Devos S; Corthals J; Moser M; Thielemans K
J Immunol; 1999 Jan; 162(1):144-51. PubMed ID: 9886380
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
